Beam Therapeutics Inc’s filing revealed that its Officer AMY SIMON acquired Company’s shares for reported $0.68 million on Apr 01 ’25. In the deal valued at $22.21 per share,30,562 shares were bought.
Then, JOHN M. EVANS bought 64,842 shares, generating $1,440,141 in total proceeds.
Before that, CHRISTINE BELLON bought 18,125 shares. Beam Therapeutics Inc shares valued at $402,556 were divested by the Officer at a price of $22.21 per share.
BofA Securities upgraded its Beam Therapeutics Inc [BEAM] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who increased its forecast for the stock in early March from “a Sector perform” to “a Sector outperform”. Cantor Fitzgerald also remained covering BEAM and has increased its forecast on January 29, 2025 with a “an Overweight” recommendation from previously “Neutral” rating. Leerink Partners revised its rating on November 06, 2024. It rated BEAM as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of BEAM
On Monday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock fall -12.07% to $19.53. Over the last five days, the stock has lost -18.66%. Beam Therapeutics Inc shares have fallen nearly -21.25% since the year began. Nevertheless, the stocks have fallen -42.49% over the past one year. While a 52-week high of $35.25 was reached on 02/18/25, a 52-week low of $20.84 was recorded on 03/31/25. SMA at 50 days reached $26.39, while 200 days put it at $25.75.
Levels Of Support And Resistance For BEAM Stock
The 24-hour chart illustrates a support level at 18.09, which if violated will result in even more drops to 16.66. On the upside, there is a resistance level at 21.17. A further resistance level may holdings at 22.82. The Relative Strength Index (RSI) on the 14-day chart is 31.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.93%. Stochastics %K at 9.83% indicates the stock is a buying.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2025-03-14, growing by 2.93 million shares to a total of 12.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 9.24 million shares. There was a rise of 24.06%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
